22-Apr-2021

Biotech Dispatch: Kazia licenses global rights to potential first-in-class oncology drug

Kazia Therapeutics (ASX:KZA) has entered into a worldwide exclusive licensing agreement and a master services agreement with European company Evotec SE for EVT801, a small molecule, first-in-class oncology drug candidate.

21-Apr-2021

Ausbiz: Three big moves in seven weeks; how Kazia is turbocharging biotech innovation

Three big moves in seven weeks; how Kazia is turbocharging biotech innovation

Kazia Therapeutics CEO James Garner is a very happy man. After securing the company's third key licence in seven weeks, he tells us about the why's and how's.

21-Apr-2021

Stockhead: Kazia Therapeutics completes third licensing deal in seven weeks

Kazia Therapeutic‘s chief executive says he could do with catching up on sleep after a “whirlwind” seven weeks in which the $185 million cancer-focused Sydney biotech completed three different cross-border licensing deals.

Kazia on Monday announced it had licensed global rights to a promising small molecule oncology drug candidate from Germany-based Evotec SE (FRA:EVT) for an upfront payment of €1 million ($1.6 million), plus contingent milestone payments of up to €308 million ($480 million).

11-Dec-2020

Associate Professor Matt Dun talks about the PNOC study in DIPG

Our collaborator, Associate Professor Matt Dun talks about the new PNOC study in an article for the Hunter Medical Research Institute (HMRI).

20-Oct-2020

CEO Dr James Garner interview with Proactive Investors on GBM AGILE

We’re pleased to share a video interview with our CEO, Dr James Garner on Proactive Investors following the recent commencement of the GBM AGILE study, which will serve as the pivotal study for registration of our lead candidate, paxalisib.

06-Oct-2020

Ausbiz, The Wall Street Transcript and Stockhead media articles

Our CEO, Dr James Garner was recently interviewed on Ausbiz to discuss Kazia’s entitlement offer, with the company successfully completing the institutional component of the offer last week, which raised $16.4 million.

28-Sep-2020

CEO, Dr James Garner interviewed by Share Café on Dana Farber collaboration

Our CEO, Dr James Garner recently conducted a video interview with Share Café following Kazia’s announcement of a collaboration with Dana-Farber Cancer Institute to investigate the use of paxalisib in primary central nervous system (CNS) lymphoma, a potential new indication for the drug.

26-Aug-2020

CEO, Dr James Garner interviewed on Share Café

Our CEO, Dr James Garner recently conducted video and print interviews with Share Café following the US Food and Drug Administration’s award of Rare Pediatric Disease Designation for paxalisib in Diffuse Intrinsic Pontine Glioma (DIPG) and Fast Track Designation for paxalisib in glioblastoma.

18-Aug-2020

Leading Australian cancer researcher, Dr Matt Dun, interviewed on Channel 7’s Sunrise

Our collaborator, Dr Matt Dun, and Kazia CEO, Dr James Garner, were interviewed on Channel 7’s Sunrise program on the development of paxalisib for Diffuse Intrinsic Pontine Glioma (DIPG) and the grant by the FDA of Rare Pediatric Disease Designation for paxalisib for the treatment of DIPG.

12-Aug-2020

Dr James Garner article in Equity magazine

Our CEO, Dr James Garner recently had an article published in EQUITY magazine – the membership magazine for the Australian Shareholders Association.

22-Jul-2020

Kazia calls for greater awareness of one of the deadliest brain cancers in the US

This Glioblastoma (GBM) Awareness Day, Australian oncology-focused biotech company, Kazia calls for greater awareness of one of the most lethal brain cancers in the US.

23-Jun-2020

Dr James Garner discusses paxalisib development with the Australian Shareholders Association

Our CEO, Dr James Garner sat down with the Australian Shareholders Association to discuss the development of our lead candidate, paxalisib, for glioblastoma.

08-Jun-2020

World Brain Tumour Day: Kazia is urging awareness of the signs and symptoms of brain tumours

On World Brain Tumour Day (June 8), Kazia is calling for greater awareness of the signs and symptoms of brain tumours, as they can often be malignant and therefore, a potentially deadly condition.

29-May-2020

World Ovarian Cancer Day: Encouraging all women to be aware of their family medical history

As May draws to a close, we’d like to look back on World Ovarian Cancer Day, which was held on May 8.

27-Apr-2020

Dr James Garner discusses paxalisib data with FNN

Our CEO, Dr James Garner recently conducted an interview with FNN which focused on the recent interim data from Kazia’s ongoing phase II trial of paxalisib in glioblastoma.

17-Mar-2020

March 2020 Shareholder Newsletter

Kazia Therapeutics is pleased to make its March 2020 newsletter available to investors.

02-Mar-2020

Dr James Garner interviewed for Switzer Financial Group’s The CEO Masterclass

Our CEO, Dr James Garner sat down with Peter Switzer to discuss Kazia’s upcoming value-driving milestones in 2020 and the development of lead program, paxalisib, for Switzer Financial Group’s The CEO Masterclass series.

12-Dec-2019

Dr James Garner discusses GBM AGILE study with Boardroom Media

Our CEO, Dr James Garner sat down with Boardroom Media to discuss Kazia joining the GBM AGILE international phase II / III study in glioblastoma with its lead program, GDC-0084.

28-Nov-2019

Interview with BioWorld

Our CEO, Dr James Garner was interviewed in BioWorld on the recent release of interim efficacy data from the phase II trial of GDC-0084 in glioblastoma as well as the overall GDC-0084 program.

28-Nov-2019

Dr James Garner discusses GDC-0084 interim efficacy data with Pitt Street Research

Our Chief Executive Officer, Dr James Garner, sat down with Stuart Roberts of Pitt Street Research in Sydney to discuss the company’s recent announcement of positive interim efficacy data from its phase II trial of GDC-0084 in glioblastoma.